中国人群食管鳞癌生存分析研究新进展

doi:10.11904/j.issn.1002-3070.2018.04.012

Abstract

Abstract: The overall burden of esophageal cancer in China is still relatively serious.Esophageal squamous cell carcinoma(ESCC)is the most important pathological type of esophageal cancer in China,accounting for more than 85%.At present,there are still many limitations on the study of the survival rate of esophageal cancer in China.It is necessary to provide information on the prognostic indicators such as the survival rate of ESCC in China based on the multi-center large-sample study to verify the existing evidence abroad and discover new features in China.The population based high-precision survival analysis can provide representative survival results,reflecting the overall prognosis of esophageal cancer in a certain area and also supply a reliable basis for the development and optimization of esophageal cancer prevention and treatment strategies.This analysis can also explore and verify the effects of esophageal cancer treatment to underly factors which provide representative material to further optimize clinical treatment strategies.This article summarizes the research progress in the survival rate and prognosis factors of esophageal cancer in China in recent years,and compares it with the international other countries,in order to provide a basis for follow-up research.

Key words: Esophageal cancer, Squamous cell carcinoma, Survival rate, Prognosis, China

CLC Number:

R735.1

DU Lingbin,WEI Wenqiang. Progress research in survival analysis of esophageal squamous cell carcinoma(ESCC)in Chinese population[J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 344-348.

References

1 Ervik M,LamF,Ferlay J.et al.Cancer Today[DB/OL].Lyon:International Agency for Research on Cancer,2016.
2 Ferlay J,Soerjomataram I,Dikshit R,et al.Cancer incidence and mortality worldwide:sources,methods and major patterns in GLOBOCAN 2012[J].Int J Cancer,2015,136(5):359-386.
3 Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
4 Howlader N,Noone AM,Krapcho M,et al.SEER cancer statistics review,1975-2014[DB/OL].USA:National Cancer Institute,2017.
5 Bohanes P,Yang D,Chhibar RS,et al.Influence of sex on the survival of patients with esophageal cancer[J].J Clin Oncol,2012,30(18):2265-2272.
6 赫捷,陈万青.2016中国肿瘤登记年报[M].北京:清华大学出版社,2017.
7 Chen W,Zheng R,Zhang S,et al.Cancer incidence and mortality in China,2013[J].Cancer Lett,2017,401:63-71.
8 Compton CC,Byrd DR,Garcia-Aguilar J,et al.Cancer survival analysis[M].New York:Springer,2012.
9 Bissonnette L,Hurd MD,Michaud PC.Individual survival curves comparing subjective and observed mortality risks[J].Health Econ,2017,26(12):285-303.
10 左婷婷,陈万青.中国乳腺癌全人群生存率分析研究进展[J].中国肿瘤临床,2016,43(14):639-642.
11 Okuyama A,Shibata A,Nishimoto H.Critical points for interpreting patients' survival rate using cancer registries:a literature review[J].J Epidemiol,2018,28(2):61-66.
12 Allemani C,Matsuda T,Di Carlo V,et al.Global surveillance of trends in cancer survival 2000-14(CONCORD-3):analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J].Lancet,2018,391(10125):1023-1075.
13 Allemani C,Weir HK,Carreira H,et al.Global surveillance of cancer survival 1995-2009:analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries(CONCORD-2)[J].Lancet,2015,385(9972):977-1010.
14 The Surveillance,Epidemiology,End Results(SEER)Program.Cancer stat facts:esophageal cancer[DB/OL].USA:National Cancer Institute,2017.
15 Zeng C,Wen W,Morgans AK,et al.Disparities by race,age,and sex in the improvement of survival for major cancers:results from the National Cancer Institute Surveillance,Epidemiology,and End Results(SEER)program in the United States,1990 to 2010[J].JAMA Oncol,2015,1(1):88-96.
16 Anderson LA,Tavilla A,Brenner H,et al.Survival for oesophageal,stomach and small intestine cancers in Europe 1999-2007:results from EUROCARE-5[J].Eur J Cancer,2015,51(15):2144-2157.
17 Zeng H,Zheng R,Guo Y,et al.Cancer survival in China,2003-2005:a population-based study[J].Int J Cancer,2015,136(8):1921-1930.
18 臧豹,赵建强,侯予龙.食管癌淋巴结转移数量与生存率的相关性[J].中华实用诊断与治疗杂志,2016,30(9):900-901.
19 李国栋.1510例食管癌患者术后生存率及预后影响因素分析[D].太原:山西医科大学,2016.
20 李学民,汤萨,彭秀青,等.1973-2005年手术治疗食管癌患者5年生存率变化分析[J].肿瘤防治研究,2014,41(3):237-242.
21 Wang J,Wu N,Zheng QF,et al.Evaluation of the 7th edition of the TNM classification in patients with resected esophageal squamous cell carcinoma[J].World J Gastroenterol,2014,20(48):18397-18403.
22 Offman J,Pesola F,Sasieni P.Trends and projections in adenocarcinoma and squamous cell carcinoma of the oesophagus in England from 1971 to 2037[J].Br J Cancer,2018,118(10):1391-1398.
23 Siewert JR,Ott K.Are squamous and adenocarcinomas of the esophagus the same disease?[J].Semin Radiat Oncol,2007,17(1):38-44.
24 Ilson DH,Ajani J,Bhalla K,et al.Phase II trial of paclitaxel,fluorouracil,and cisplatin in patients with advanced carcinoma of the esophagus[J].J Clin Oncol,1998,16(5):1826-1834.
25 Rizk NP,Venkatraman E,Bains MS,et al.American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma[J].J Clin Oncol,2007,25(5):507-512.
26 Rizk N,Venkatraman E,Park B,et al.The prognostic importance of the number of involved lymph nodes in esophageal cancer:implications for revisions of the American Joint Committee on Cancer staging system[J].J Thorac Cardiovasc Surg,2006,132(6):1374-1381.
27 Kattan MW,Hess KR,Amin MB,et al.American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine[J].CA Cancer J Clin,2016,66(5):370-374.
28 Rice TW,Gress DM,Patil DT,et al.Cancer of the esophagus and esophagogastric junction-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual[J].CA Cancer J Clin,2017,67(4):304-317.
29 Lin WC,Ding YF,Hsu HL,et al.Value and application of trimodality therapy or definitive concurrent chemoradiotherapy in thoracic esophageal squamous cell carcinoma[J].Cancer,2017,123(20):3904-3915.
30 Xi M,Xu C,Liao Z,et al.Comparative outcomes after definitive chemoradiotherapy using proton beam therapy versus intensity modulated radiation therapy for esophageal cancer:a retrospective,single-institutional analysis[J].Int J Radiat Oncol Biol Phys,2017,99(3):667-676.
31 Merkow RP,Bilimoria KY,Keswani RN,et al.Treatment trends,risk of lymph node metastasis,and outcomes for localized esophageal cancer[J].J Natl Cancer Inst,2014,106(7):1-8.
32 方文涛.通过食管癌TNM新分期(第八版)解读2017年NCCN食管鳞癌诊疗指南[J].中华胃肠外科杂志,2017,10(20):1122-1126.
33 Strong VE,D'amico TA,Kleinberg L,et al.Impact of the 7th Edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers[J].J Natl Compr Canc Netw,2013,11(1):60-66.
34 王澜,李晓旭,韩春,等.食管癌长期生存患者临床特征及治疗相关因素分析[J].中华放射肿瘤学杂志,2016,25(6):565-570.
35 景奇,陈诗奉.新辅助化疗联合手术与单纯手术治疗食管癌疗效及安全性Meta分析[J].重庆医学,2011,40(32):3236-3238.
36 刘爱娜,黄镜,蔡锐刚,等.138例晚期食管癌的化疗疗效和预后因素分析[J].癌症,2008,27(4):400-406.
37 Raja SG,Salhiyyah K,Nagarajan K.Does neoadjuvant chemotherapy improve survival in patients with resectable thoracic oesophageal cancer?[J].Interact Cardiovasc Thorac Surg,2007,6(5):661-664.
38 Kim YC,Park KO,Choi IS,et al.A comparison of serum CYFRA 21-1 and SCC Ag in the diagnosis of squamous cell lung carcinoma[J].Korean J Int Med,1996,11(1):50-57.
39 Shimada H,Nabeya Y,Okazumi S,et al.Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma[J].Surgery,2003,133(5):486-494.
40 Lagarde SM,Ten Kate FJ,Richel DJ,et al.Molecular prognostic factors in adenocarcinoma of the esophagus and gastroesophageal junction[J].Ann Surg Oncol,2007,14(2):977-991.
41 Markar SR,Mackenzie H,Lagergren P,et al.Surgeon age in relation to prognosis after esophageal cancer resection[J].Ann Surg,2017,4(265):639-643.
42 Thrift AP,Nagle CM,Fahey PP,et al.The influence of prediagnostic demographic and lifestyle factors on esophageal squamous cell carcinoma survival[J].Int J Cancer,2012,131(5):759-768.
43 Li XC,Wang M,Yang M,et al.A mutational signature associated with alcohol consumption and prognostically significantly mutated driver genes in esophageal squamous cell carcinoma[J].Ann Oncol,2018,29(4):938-944.
44 Xia Y,Li YH,Chen Y,et al.A phase II trial of concurrent chemoradiotherapy with weekly paclitaxel and carboplatin in advanced oesophageal carcinoma[J].Int J Clin Oncol,2018,23(3):458-465.
45 Wu N,Zhu Y,Kadel D,et al.The prognostic influence of body mass index,resting energy expenditure and fasting blood glucose on postoperative patients with esophageal cancer[J].BMC Gastroenterol,2016,16(1):142-153.
46 Boshier PR,Ziff C,Adam ME,et al.Effect of perioperative blood transfusion on the long-term survival of patients undergoing esophagectomy for esophageal cancer:a systematic review and meta-analysis[J].Dis Esophagus,2017,4(31):1-10.
47 Revels SL,Morris AM,Reddy RM,et al.Racial disparities in esophageal cancer outcomes[J].Ann Surg Oncol,2013,20(4):1136-1141.

[1]	WANG Xiaoya,XIAO Bin,LIAO Yang,TANG Rongzhi,SUN Zhaohui,LI Linhai. Expression of CXCR family proteins in different subtypes of breast cancer and their clinical prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 206-210.
[2]	FENG Yue,XING Linan,WANG Zhao,ZHANG Yunyan. Correlation between NLR and prognosis of concurrent chemoradiotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 284-288.
[3]	BAI Xiaobin, HUO Longwei, XIE Wanfu, XU Gaofeng, WANG Maode. Expression of Chk1 in glioblastoma and its association with tumor biological behavior and prognosis survival [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 122-127.
[4]	SHI Xiaokang, DING Youming, WANG Bin, YU Bin, XU Yu. Expression and clinical significance of UBE2T in primary liver cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 128-133.
[5]	LU Jiaoyun, ZHANG Qingyuan. Advances in laboratory markers in the prognosis of diffuse large B-cell lymphoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 183-187.
[6]	ZHAO Fengjuan, WANG Qi, REN Yunhong, WEI Jueling, LI Lequn, ZHAO Xinhua, TANG Juan, YOU Xuemei. Changes of serum CRP and hs-CRP levels in patients with liver cancer and depression and their influence on prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 27-33.
[7]	ZHANG Fengchun, JIANG Ying, LIU Zhaonan, YAN Ningning, CUI Hongquan, XU Yingchun. Prognostic significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in systemic inflammation-related indicators in gastric cancer patients after radical resection [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 34-39.
[8]	MA Jianli, ZHANG Minghui, JI Hongfei, XU Xiangying. Clinical significance of combined detection of PD-L1 protein and CD8⁺TILs in resected lung adenocarcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 40-46.
[9]	YANG Hongbo, SHI Jie, YE Yong, LI Wencheng, DENG Zhaoping. Expression of COL5A2 in bladder cancer tissues and its correlation with clinicopathological features and prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 52-56.
[10]	LIU Zhongyang, YUAN Xin, ZHOU Wen, LI Xiaoliang, FAN Limao. Therapeutic effect of minimally invasive small incision surgery on patients with early thoracic esophageal cancer and its influence in pain [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 57-61.
[11]	WANG Lei, JIANG Huanyu, SONG Kaibin. miR-219 regulates PRKCI expression in tongue squamous cell carcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 510-514.
[12]	YU Fang, ZHAO Pei. The role and mechanism of TRAP1 in the development of esophageal cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 515-519.
[13]	WANG Yalong, LYU Zhangyan, ZHANG Fan, FENG Xiaoshuang, WEI Luopei, LI Xin, WEN Yan, GAO Yushun, XUE Qi, GAO Shugeng, TAN Fengwei. Relationship between human papillomavirus infection and prognosis of lung cancer:A meta-analysis [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 520-526.
[14]	TANG Shuli, HE Kuangbang, ZHANG Chunhui, CHENG Jianan, ZHANG Yanqiao. Expression of miR-320a and CYLD in gastric cancer and its relationship with clinicopathological characteristics and prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 538-544.
[15]	XIAO Hongwei, CHEN Sheng, WANG Yanliang, SU Xueliang. The prognostic and influence factors analysis of transanal local resection for stage T₁ rectal cancer with the distance from anal margin ≤8 cm [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 545-549.

Progress research in survival analysis of esophageal squamous cell carcinoma(ESCC)in Chinese population

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments